Type 2 Diabetes (T2D) Treatments

Find Type 2 Diabetes (T2D) Treatments

Generic Name

Pioglitazone

Brand Names

Alogliptin, OSENI

FDA approval date: July 15, 1999

Classification: Peroxisome Proliferator Receptor alpha Agonist

Form: Tablet

What is Alogliptin (Pioglitazone)?

Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin and pioglitazone tablets are a combination of alogliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone, a thiazolidinedione agonist of peroxisome proliferator receptor gamma, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus. Limitations of Use Alogliptin and pioglitazone tablets are not recommended for use in patients with type 1 diabetes mellitus.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Who is this study for: Patients with Multiple Sclerosis

Enrollment Status: Recruiting

Publish Date: June 18, 2026

Intervention Type: Drug

Study Drugs: Pioglitazone, Clemastine Fumarate, Hydroxychloroquine, Dantrolene

Study Phase: Phase 1/Phase 2

Background: In people with multiple sclerosis (MS), brain and cerebrospinal fluid (CSF) biomarkers indicate inflammation or disease. Researchers want to see if 4 drugs given alone or combined affect MS biomarkers. They want to see if a change in biomarker levels can predict which drugs a person with MS might respond to.

Protocol lV: SGLT2 Inhibitors, Pioglitazone and Ketone Production in Type 2 Diabetes Mellitus

Enrollment Status: Recruiting

Publish Date: May 12, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).

Comparing Enavogliflozin and Pioglitazone as Add-ons to Metformin With/Without Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes

Enrollment Status: Recruiting

Publish Date: May 05, 2026

Intervention Type: Drug

Study Phase: Phase 4

Summary: The current study aimed to thoroughly compare a thiazolidinedione and an sodium-glucose cotransporter-2 (SGLT2) inhibitor regarding various clinical issues including atherosclerosis. Enavogliflozin is compared to Pioglitazone in the glucose-lowering effects of adding to the treatment of patients with type 2 diabetes whose HbA1c levels are not controlled by Metformin with or without DPP-4 inhibitor...

View All Clinical Trials